Last updated: 11/03/2018 11:30:59
Incidence of expression of tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Analysis of the incidence of expression of tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer
Trial description: This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer.
Timeframe: Up to 1 year
Secondary outcomes:
Not applicable
Interventions:
Other: Data acquisition and analysis
Enrollment:
156
Observational study model:
Cohort
Primary completion date:
2008-15-01
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Neoplasms, Urinary Bladder
Product
GSK1711805A
Collaborators
Not applicable
Study date(s)
January 2008 to January 2008
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
No
- For inclusion of a tissue sample, all of the following criteria must be met:
- – The patient had pathologically proven bladder cancer (any stage).
- Not applicable.
Inclusion and exclusion criteria
Inclusion criteria:
- For inclusion of a tissue sample, all of the following criteria must be met: – The patient had pathologically proven bladder cancer (any stage). – All the data required are available from patient's records. There are no restrictions regarding operative technique (cystectomy or cystoscopy). – Many patients may no longer be alive, or no longer be in contact with the investigation sites. Thus, patients will not be required to give their informed consent before inclusion in the study.
Exclusion criteria:
- Not applicable.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2008-15-01
Actual study completion date
2008-15-01
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website